Eisai (ESALY) News Today $61.51 -1.33 (-2.11%) As of 01/30/2023 Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Eisai stock price target cut to JPY5,000 at Citi, retains Buy ratingFebruary 10, 2025 | msn.comEli Lilly's Alzheimer's Drug Raises Hopes but Faces Regulatory Hurdles in EuropeOctober 14, 2024 | finance.yahoo.comAlzheimer's drug Leqembi promises to give patients more time, but they face a long road to treatmentSeptember 8, 2024 | cnbc.comThis matcha set helped me break my coffee addiction and I’ve never looked backSeptember 2, 2024 | msn.comEisai Co., Ltd. (ESAIY)July 27, 2024 | finance.yahoo.comBiogen/Eisai's Alzheimer's Drug Leqembi Gets 'No Go' From European Drug Regulator's Advisory Panel, Cites Serious Side EventsJuly 26, 2024 | msn.comEisai Co. Ltd. ADRMarch 29, 2024 | wsj.comEisai Co LtdMarch 23, 2024 | reuters.comEisai Co Ltd 4523March 20, 2024 | morningstar.comBIIB Mar 2024 210.000 callFebruary 15, 2024 | finance.yahoo.comBIIB Feb 2024 227.500 callFebruary 15, 2024 | finance.yahoo.comBIIB Mar 2024 235.000 callFebruary 15, 2024 | finance.yahoo.comBIIB Mar 2024 205.000 putFebruary 14, 2024 | finance.yahoo.comESALF Eisai Co., Ltd.January 12, 2024 | seekingalpha.comMerck Says Phase 3 LEAP-001 Trial Evaluating KEYTRUDA Plus LENVIMA Did Not Meet EndpointsDecember 8, 2023 | markets.businessinsider.comJapan's Regulatory Authority Approves Biogen/Eisai's Alzheimer Treatment LeqembiSeptember 25, 2023 | msn.comMerck-Eisai Partnered Two Keytruda/Lenvima Combo Trials Flunk In Certain Types Of Lung CancerSeptember 22, 2023 | msn.comBiogen Shares Fall After FDA Approval Of Alzheimer's Drug Leqembi (ESALY)Biogen's shares decline after approval of Alzheimer's treatment Leqembi, which modestly slows cognitive decline. Analysts see hurdles to the rollout.July 10, 2023 | marketbeat.comFDA Grants Traditional Approval To Eisai's Leqembi To Treat Adult Patients With Alzheimer's DiseaseJuly 6, 2023 | markets.businessinsider.comAlzheimer's Drug Leqembi Faces Hurdles in Europe: Concerns Over Health Risks and Healthcare ResourcesJune 13, 2023 | benzinga.comFDA Panel Recommends Full Approval For Biogen And Eisai's Alzheimer's Drug LeqembiJune 11, 2023 | markets.businessinsider.comBernie Sanders Takes on High Costs of Alzheimer's Treatment Leqembi, Calls Price Tag 'Unconscionable'June 8, 2023 | msn.comUTHR or ESALY: Which Is the Better Value Stock Right Now?January 9, 2023 | finance.yahoo.comFDA approves treatment for people with mild forms of Alzheimer’sJanuary 6, 2023 | finance.yahoo.comDespite Safety Concerns, Analysts Are Bullish On Biogen's Second Alzheimer's CandidateNovember 30, 2022 | finance.yahoo.comBiogen rallies Alzheimer’s drug developers after full data for lecanemabNovember 30, 2022 | seekingalpha.comOpen Questions On Safety Lingers After Eisai-Biogen's Detailed Lecanemab Data For Alzheimer'sNovember 30, 2022 | finance.yahoo.comBiogen's lecanemab shows less cognitive decline with Alzheimer's, but more brain swellingNovember 30, 2022 | seekingalpha.comBiogen and Eisai’s Alzheimer’s Data Confirm Benefit. Questions Still Loom.November 30, 2022 | barrons.comBiogen drops after report on second death linked to Alzheimer’s candidateNovember 28, 2022 | seekingalpha.comUTHR vs. ESALY: Which Stock Is the Better Value Option?November 28, 2022 | finance.yahoo.comAfter Rallying 50% in the Last 2 Months, Is Biogen Stock Still a Buy?November 17, 2022 | msn.comRoche's Alzheimer's Flop Trial Removes One Competitor, But Reimbursement Debate LingersNovember 15, 2022 | finance.yahoo.comFY2024 Earnings Estimate for Eisai Co., Ltd. (OTCMKTS:ESALY) Issued By Jefferies Financial GroupEisai Co., Ltd. (OTCMKTS:ESALY - Get Rating) - Equities research analysts at Jefferies Financial Group dropped their FY2024 earnings estimates for Eisai in a research report issued on Sunday, October 30th. Jefferies Financial Group analyst S. Barker now forecasts that the company will post earninNovember 2, 2022 | marketbeat.comPatient Death in Alzheimer's Study May Limit Drug's ReachOctober 29, 2022 | msn.comBiogen Alzheimer’s data de-risked beta amyloid hypothesis - Roche executiveOctober 18, 2022 | seekingalpha.comDespite Advancement, Benefits From Alzheimer's Drugs May Be Limited, Say ResearchersOctober 18, 2022 | finance.yahoo.comBiogen shares soar on landmark Alzheimer's data, lift rivalsSeptember 29, 2022 | investing.comMany Alzheimer's drug developers close significantly higher thanks to Biogen, Eisai dataSeptember 28, 2022 | seekingalpha.comThis Analyst Believes Biogen's Lecanemab Data Not 'Slam Dunk' For Complete CMS ApprovalSeptember 28, 2022 | finance.yahoo.com2 Sympathy Plays To Watch For In The Wake Of Biogen's Positive Alzheimer's Drug DataSeptember 28, 2022 | markets.businessinsider.comAnalysis-Alzheimer's drug breakthrough big boost for Roche, Eli LillySeptember 28, 2022 | investing.comBiogen, Eisai drive rally in Alzheimer’s stocks as lecanemab succeeds in late-stage trialSeptember 28, 2022 | seekingalpha.comBiogen and Lilly: How I'm Playing the Alzheimer's Drug Stocks GameSeptember 28, 2022 | realmoney.thestreet.comIs This the First Alzheimer's Drug to Actually Work?September 28, 2022 | msn.comEisai says Alzheimer's drug succeeds in slowing cognitive declineSeptember 28, 2022 | investing.comBiogen, Eisai Alzheimer's candidate lecanemab meets primary endpoint in late-stage trialSeptember 28, 2022 | seekingalpha.comPharmaceutical Makers Eisai and Biogen Claim Success in Latest Alzheimer’s Drug TrialSeptember 27, 2022 | barrons.comEisai Co., Ltd (ADR) (OTC: ESALY)September 24, 2022 | fool.comCan We Beat Alzheimer’s? Biogen and Eisai’s Latest Drug Trial Will Offer Clues.September 23, 2022 | barrons.com Get Eisai News Delivered to You Automatically Sign up to receive the latest news and ratings for ESALY and its competitors with MarketBeat's FREE daily newsletter. Email Address ESALY Media Mentions By Week ESALY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ESALY News Sentiment▼0.000.67▲Average Medical News Sentiment ESALY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ESALY Articles This Week▼00▲ESALY Articles Average Week Get Eisai News Delivered to You Automatically Sign up to receive the latest news and ratings for ESALY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies VCISY News Today CMPGY News Today BMWYY News Today BAMXF News Today HEINY News Today DHLGY News Today JAPAY News Today HOCPY News Today SGAPY News Today DNZOY News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:ESALY) was last updated on 3/6/2025 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | Sponsored77 Hedge Funds Are Betting On This Off-Radar MineralWith surging prices... supply shortages... and growing demand, hedge funds are betting big on potash. In fa...The Tomorrow Investor | SponsoredAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredTrillion-Dollar Crypto PlayAI is Creating Fortunes… (but not where you think!) Bryce Paul and the team at Crypto101 just released a br...Crypto 101 Media | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eisai Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eisai With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ESALY Stock Alerts